1. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Issue 1 (January 2016) Authors: du Bois, Andreas; Kristensen, Gunnar; Ray-Coquard, Isabelle; Reuss, Alexander; Pignata, Sandro; Colombo, Nicoletta; Denison, Ursula; Vergote, Ignace; del Campo, Jose M; Ottevanger, Petronella; Heubner, Martin; Minarik, Thomas; Sevin, Emmanuel; de Gregorio, Nikolaus; Bidziński, Mariusz; Pfisterer,... Journal: Lancet oncology Issue: Volume 17:Issue 1(2016:Feb.) Page Start: 78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗